Randomized Clinical Trial Comparing Orsiro1 Drug-Eluting Stent with Xience2 DES
- In this 1,334 patient large, international, randomized trial Orsiro demonstrated statistically significantly lower Target Lesion Failure (TLF) rates compared to Xience at 12 months (Orsiro 6.2%, Xience 9.6%, p-value = 0.04)
- Procedure success was significantly higher with Orsiro (Orsiro 93.8%, Xience 90.1%, p-value = 0.02), mainly driven by a higher rate of in-hospital Myocardial Infarction (MI) associated with Xience (Orsiro 3.9%, Xience 6.7%, p-value = 0.03)
- Stent Thrombosis (ST) rate was numerically lower in the Orsiro cohort (Orsiro 0.5%, Xience 1.2%, p-value = 0.18)
TLF at 12 months defined as a composite of Cardiac Death (CD), Target-Vessel MI (TV-MI) or any clinically-driven Target Lesion Revascularization (cd-TLR)
Pre-specified secondary endpoints:
- Components of the primary endpoint
- Target Vessel Failure (TVF) and individual TVF components
- MI and/or CD
- ST (all, definite, definite/probable, probable, possible ST)3
- Success rates (device, lesion and procedure)
© BIOTRONIK AG – All rights reserved.
Specifications are subject to modification, revision and improvement.
Kandzari D. et al., Ultrathin Bioresorbable Polymer Sirolimus-Eluting Stents versus Thin Durable Polymer Everolimus-Eluting Stents in Patients Undergoing Coronary Revascularisation (BIOFLOW-V): a randomised trial, 2017, The Lancet.
1 CAUTION - Investigational device. Limited by United States law to investigational use.
2 Xience is a registered trademark of Abbott Cardiovascular Systems Inc.
3 according to Academic Research Consortium (ARC) criteria for acute, subacute, late, very late and cumulative stent thrombosis
4 Kandzari D. BIOFLOW-V: A Prospective Randomized Multicenter Study to Assess the SaFety and Effectiveness of the Orsiro SiroLimus Eluting Coronary Stent System in the Treatment Of Subjects With up to Three De Novo or Restenotic Coronary Artery Lesions Science. Presentation at ESC 2017.